DLL3
ENSG00000090932
Target class
Unclassified protein
Chromosome
19
Approved drugs
1
Clinical candidates (approved and in development)
2
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- No
- Other names
- SCDO1
- Target name
- DLL3
- Gene name
- Delta like canonical Notch ligand 3
- Gene symbol
- DLL3
- Protein name
- Delta-like protein 3 (Drosophila Delta homolog 3) (Delta3)
- Gene biotype
- Protein coding
- Gene family
- Canonical Notch ligands
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 15
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 11.43
- Tissue specificity (Gini)
- 0.756
- Tissue specificity (tau)
- 0.87
- KEGG gene identifiers
- hsa:10683
- Protein interaction confidence
- 0.887917
- Protein interaction partners
- 12
- R-HSA-9793380
- R-HSA-9824272
- End position
- 39508481
- Start position
- 39498895
- Chromosome
- 19
- Strand
- Forward
- Membrane
- Single-pass type I membrane protein .
- Golgi apparatus
- Nucleoplasm
- Plasma membrane
- Tissue specificity (tau)
- 0.869856
- Expression inequality (Gini)
- 0.755981
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)
- 11.43
- Brain - Hypothalamus
- 8.56
- Brain - Amygdala
- 8.27
- Brain - Anterior cingulate cortex (BA24)
- 6.84
- Brain - Caudate (basal ganglia)
- 6.47
Expression in transcripts per million
- Brain - Nucleus accumbens (basal ganglia)11.43
- Brain - Hypothalamus8.56
- Brain - Amygdala8.27
- Brain - Anterior cingulate cortex (BA24)6.84
- Brain - Caudate (basal ganglia)6.47
- Brain - Hippocampus6.24
- Brain - Frontal Cortex (BA9)6.2
- Brain - Cortex5.53
- Brain - Putamen (basal ganglia)5.45
- Pituitary4.95
- Brain - Substantia nigra4.48
- Testis3.28
- Brain - Spinal cord (cervical c-1)3.14
- Brain - Cerebellar Hemisphere2.89
- Brain - Cerebellum2.47
- Cells - Cultured fibroblasts0.91
- Cells - EBV-transformed lymphocytes0.61
- Ovary0.3
- Thyroid0.26
- Spleen0.18
- Nerve - Tibial0.17
- Small Intestine - Terminal Ileum0.14
- Vagina0.1
- Cervix - Endocervix0.09
- Colon - Sigmoid0.09
And 29 more, listed on the interactive page.
Biological processes
- GO:0001501
Related records
Trials (51)
- A Long-Term Study of Rovalpituzumab Tesirine
- A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)
- A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
- A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
- A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
- A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer
- A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
- A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
- A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
- A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
- A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)
- A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
- A Study of Tarlatamab for People With Prostate Cancer
- A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
- A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer
- A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
- AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
- Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer
- Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment
- Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
Drugs (2)
- Rovalpituzumab tesirine Delta-like protein 3 binding agent
- Tarlatamab Delta-like protein 3 binding agent